Ozone Autohemotherapy in Covid19

Phase 2

• Conditions: Coronavirus infection.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20190618043923N4
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Being 20-60 years of age
Having a positive reverse-transcriptase polymerase chain reaction test for SARS-CoV-2
Being admitted to the intensive care unit
Receiving invasive mechanical ventilation that began a short time before admission or in the intensive care unit

Exclusion Criteria

Patients with an anticipated survival length of fewer than 24?hours
Patients with a body mass index of 35 kg/m2 and over
Patients with a history of blood disorders
Patients with a history of renal or liver failure or chronic obstructive pulmonary disease
Pregnant or lactating women
Patients who were joined in other clinical trials

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete Blood cell count and diffrential count. Timepoint: Complete Blood cell count and diffrential count at the beginning of the study (before the intervention) and 7, 14 and 21 days after the start of ozone autohemotherapy. Method of measurement: Biochemical analysis.;Liver function tests. Timepoint: Liver function tests at the beginning of the study (before the intervention) and 7, 14 and 21 days after the start of ozone autohemotherapy. Method of measurement: Biochemical analysis.;Renal function tests. Timepoint: Renal function tests at the beginning of the study (before the intervention) and 7, 14 and 21 days after the start of ozone autohemotherapy. Method of measurement: Biochemical analysis.

Secondary Outcome Measures

Name	Time	Method
Mechanical ventilator weaning time. Timepoint: Mechanical ventilator weaning time during the study after the start of ozone autohemotherapy. Method of measurement: Comment by the treating physician.